• Go to navigation_nb
  • Go to content_nb
halsbrann.com

You are here

  • Forsiden
  • Mage-tarm sykdommer
  • Helicobacter pylori
  • Referanser

Astrazeneca global websites

  • AstraZeneca-nettsteder

title_nb

  • Forsiden
  • E-læring
  • Gastrointestinal news
  • Nexium®
  • MUPS®
  • Legemidler
  • Mage-tarm sykdommer
    • Diare
    • Dyspepsi
    • GERD
    • Helicobacter pylori
      • Om ulcus
      • Historie
      • Epidemiologi
      • Diagnostikk
      • Indikasjoner for behandling
      • Behandling av infeksjon
      • Risikofaktorer for mislykket behandling
      • Sekundær behandling
      • Behandling av undergrupper av pasienter
      • Behandling av friske funnet ved screening
      • Mekanisme for utvikling av ulcus duodeni
      • Negativ idiopatisk ulcussykdom
      • "Test and Treat" hva er det?
      • Referanser
    • Ulcus
  • Veiledning til pasienter
  • Vitenskapelige kilder
  • Andre nettsteder
  • Site map

Referanser

  1. Penston JG, Mistry KR. Eradication of Helicobacter pylori in general practice. Aliment Pharmacol Ther 1996;10(2):139-45.
  2. Cheng Y, Macera CA, Davis DR, Blair SN. Physical activity and peptic ulcers. Does physical activity reduce the risk of developing peptic ulcers? West J Med, 2000:101-7.
  3. Rigas B, Feretis C, Papavassiliou ED. John Lykoudis: an unappreciated discoverer of the cause and treatment of peptic ulcer disease. Lancet 1999;354(9190):1634-5.
  4. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;1(8390):1311-5.
  5. Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ. Attempt to fulfil Koch's postulates for pyloric Campylobacter. Med J Aust 1985;142(8):436-9.
  6. Morris A, Nicholson G. Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol 1987;82(3):192-9.
  7. McNulty CA, Gearty JC, Crump B, Davis M, Donovan IA, Melikian V, et al. Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. Br Med J (Clin Res Ed) 1986;293(6548):645-9.
  8. Wilhelmsen I, Haug TT, Ursin H, Berstad A. Effect of short-term cognitive psychotherapy on recurrence of duodenal ulcer: a prospective randomized trial. Psychosom Med 1994;56(5):440-8.
  9. Haruma K, Okamoto S, Kawaguchi H, Gotoh T, Kamada T, Yoshihara M, et al. Reduced incidence of Helicobacter pylori infection in young Japanese persons between the 1970s and the 1990s. J Clin Gastroenterol 1997;25(4):583-6.
  10. Kosunen TU, Aromaa A, Knekt P, Salomaa A, Rautelin H, Lohi P, et al. Helicobacter antibodies in 1973 and 1994 in the adult population of Vammala, Finland. Epidemiol Infect 1997;119(1):29-34.
  11. Banatvala N, Mayo K, Megraud F, Jennings R, Deeks JJ, Feldman RA. The cohort effect and Helicobacter pylori. J Infect Dis 1993;168(1):219-21.
  12. Moayyedi P, Forman D, Braunholtz D, Feltbower R, Crocombe W, Liptrott M, et al. The proportion of upper gastrointestinal symptoms in the community associated with Helicobacter pylori, lifestyle factors, and nonsteroidal antiinflammatory drugs. Leeds HELP Study Group. Am J Gastroenterol 2000;95(6):1448-55.
  13. Everhart JE, Kruszon-Moran D, Perez- Perez GI, Tralka TS, McQuillan G. Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States. J Infect Dis 2000;181(4):1359-63.
  14. Goodman KJ, Correa P. Transmission of Helicobacter pylori among siblings. Lancet 2000;355(9201):358-62.
  15. Lam SK. Differences in peptic ulcer between East and West. Baillieres Best Pract Res Clin Gastroenterol 2000;14(1):41-52.
  16. Olafsson S, Berstad A. Therapy and diagnostic tests used for Helicobacter pylori infection in the Scandinavian countries in 1998. Scand J Gastroenterol 1999;34(9):849-55.
  17. Binek J, Fantin AC, Meyenberger C. Attitude to Helicobacter pylori infection among Swiss gastroenterologists. Schweiz Med Wochenschr 1999;129(11):441-5.
  18. Prince MI, Osborne JS, Ingoe L, Jones DE, Cobden I, Barton JR. The CLO test in the UK: inappropriate reading and missed results. Eur J Gastroenterol Hepatol 1999;11(11):1251-4.
  19. Maconi G, Vago L, Nebuloni E, Porro GB. Eradication of Helicobacter pylori, improvement of gastritis, and the normalization of the hyperproliferative state of gastric mucosa did not prevent a case of gastric cancer [letter]. J Clin Gastroenterol 1999;28(2):178-9.
  20. Heep M, Scheibl K, Degrell A, Lehn N. Transport and storage of fresh and frozen gastric biopsy specimens for optimal recovery of Helicobacter pylori. J Clin Microbiol 1999;37(11):3764-6.
  21. Leide-Svegborn S, Stenstrom K, Olofsson M, Mattsson S, Nilsson LE, Nosslin B, et al. Biokinetics and radiation doses for carbon-14 urea in adults and children undergoing the Helicobacter pylori breath
    test. Eur J Nucl Med 1999;26(6):573-80.
  22. Laine L, Estrada R, Trujillo M, Knigge K, Fennerty MB. Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann Intern Med 1998;129(7):547-50.
  23. Cutler AF, Elnaggar M, Brooks E, O'Mara K. Effect of standard and high dose ranitidine on [13C]urea breath test results. Am J Gastroenterol 1998;93(8):1297-9.
  24. Connor SJ, Ngu MC, Katelaris PH. The impact of short-term ranitidine use on the precision of the 13C- urea breath test in subjects infected with Helicobacter pylori. Eur J Gastroenterol Hepatol 1999;11(10):1135-8.
  25. Schilling D, Jakobs R, Peitz U, Sulliga M, Stolte M, Riemann JF, et al. Diagnostic Accuracy of (13)C-Urea Breath Test in the Diagnosis of Helicobacter pylori Infection in Patients with Partial Gastric Resection due to Peptic Ulcer Disease. A prospective multicenter study. Digestion 2001;63(1):8-13.
  26. de Boer WA, de Laat L, Megraud F. Diagnosis of Helicobacter pylori
    infection. Curr Opin Gastroenterol 2000;16 (suppl):S5-S10.
  27. Vaira D, Holton J, Menegatti M, Ricci C, Gatta L, Geminiani A, et al. Invasive and non-invasive tests for Helicobacter pylori infection [In Process Citation]. Aliment Pharmacol Ther 2000;14 Suppl 3:13-22.
  28. Gisbert JP, Cruzado AI, Cabrera MM, Carpio D, Benito LM, Perez Poveda JJ, et al. [«Rapid» serology for the diagnosis of Helicobacter pylori infection. Evaluation of its accuracy compared with a goldstandard and its concordance with «classic» serology]. Gastroenterol Hepatol 2000;23(4):159-64.
  29. Stone MA, Mayberry JF, Wicks AC, Livsey SA, Stevens M, Swann RA, et al. Near patient testing for Helicobacter pylori: a detailed evaluation of the Cortecs Helisal Rapid Blood test. Eur J Gastroenterol Hepatol 1997;9(3):257- 60.
  30. Mowat C, Murray L, Hilditch TE, Kelman A, Oien K, McColl KE. Comparison of helisal rapid blood test and 14C-urea breath test in determining Helicobacter pylori status and predicting ulcer disease
    in dyspeptic patients. Am J Gastroenterol 1998;93(1):20-5.
  31. Loy CT, Irwig LM, Katelaris PH, Talley NJ. Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis. Am J Gastroenterol 1996;91(6):1138-44.
  32. de Boer WA, Lerang F. Serology for follow-up of Helicobacter therapy. Eur J Gen Pract 1999;5:162.
  33. de Boer WA. Topics in Helicobacter pylori infection: Focus on a «Search-and-Treat» strategy for ulcer disease. Scand J Gastroenterol 2000;35(Suppl 235):4-9. 
  34. Vaira D, Malfertheiner P, Megraud F, Axon AT, Deltenre M, Hirschl AM, et al. Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. HpSA European study group [see
    comments]. Lancet 1999;354(9172): 30-3.
  35. Vaira D, Malfertheiner P, Megraud F, Axon AT, Deltenre M, Gasbarrini G, et al. Noninvasive antigen-based assay for assessing Helicobacter pylori eradication: a European multicenter study. The
    European Helicobacter pylori HpSA Study Group. Am J Gastroenterol 2000;95(4):925-9.
  36. Ishihara S, Kaji T, Kawamura A, Rumi MA, Sato H, Okuyama T, et al. Diagnostic accuracy of a new non-invasive enzyme immunoassay for detecting Helicobacter pylori in stools after eradication therapy. Aliment Pharmacol Ther 2000;14(5):611-4.
  37. Caselli M, Zaffoni E, Trevisani L, Sartori S, Avisi V. Diagnosis of Helicobacter pylori infection by HpSA test (correspondence). Lancet
    1999;354:1209-1211.
  38. Malfertheiner P, Megraud F, O'Morain C, Bell D, Bianchi Porro G, Deltenre M, et al. Current European concepts in the management of Helicobacter pylori infection--the Maastricht Consensus Report. The European Helicobacter pylori Study Group (EHPSG). Eur J Gastroenterol Hepatol 1997;9(1):1-2.
  39. The Maastricht 2-2000 Consensus Report. http://www.helicobacter.org/ehpsg_guidelines_patients_2000.htm 2000.
  40. Penston JG. Review article: Helicobacter pylori eradication--understandable caution but no excuse for inertia [see comments]. Aliment Pharmacol Ther 1994;8(4):369-89.
  41. Tytgat GN. Peptic ulcer and Helicobacter pylori: eradication and relapse. Scand J Gastroenterol Suppl 1995;210:70-2.
  42. Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and
    gastric ulcer recurrence: a review. Gastroenterology 1996;110(4):1244-52.
  43. Wong BC, Lam SK, Lai KC, Hu WH, Ching CK, Ho J, et al. Triple therapy for Helicobacter pylori eradication is more effective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study.
    Aliment Pharmacol Ther 1999;13(3):303-9.
  44. Malfertheiner P, Leodolter A, Peitz U. Cure of Helicobacter pylori-associated ulcer disease through eradication. Baillieres Best Pract Res Clin Gastroenterol 2000;14(1):119-32.
  45. Gilvarry J, Buckley MJ, Beattie S, Hamilton H, O'Morain CA. Eradication of Helicobacter pylori affects symptoms in non-ulcer dyspepsia [see comments]. Scand J Gastroenterol 1997;32(6):535- 40.
  46. McColl K, Murray L, El-Omar E, Dickson A, El-Nujumi A, Wirz A, et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998;339(26):1869-74.
  47. McColl KE, el-Nujumi A, Murray L, el- Omar E, Gillen D, Dickson A, et al. The Helicobacter pylori breath test: a surrogate marker for peptic ulcer disease in dyspeptic patients. Gut1997;40 (3):302-6.
  48. Blum AL, Talley NJ, O'Morain C, van Zanten SV, Labenz J, Stolte M, et al. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med 1998;339(26):- 1875-81.
  49. Talley NJ, Janssens J, Lauritsen K, Racz I, Bolling-Sternevald E. Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group . Bmj 1999;318(7187):833-7.
  50. Talley NJ, Vakil N, Ballard ED, 2nd, Fennerty MB. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med 1999;341(15):1106-11.
  51. Greenberg PD, Cello JP. Lack of effect of treatment for Helicobacter pylori on symptoms of nonulcer dyspepsia [see comments]. Arch Intern Med 1999;159(19):2283-8.
  52. Miwa H, Hirai S, Nagahara A, Murai T, Nishira T, Kikuchi S, et al. Cure of Helicobacter pylori infection does not improve symptoms in non- ulcer dyspepsia patients-a double-blind placebo-controlled study. Aliment Pharmacol Ther 2000;14(3):317-24.
  53. Moayyedi P, Soo S, Deeks J, Forman D, Mason J, Innes M, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia [In Process Citation]. Bmj 2000;321(7262):659-64.
  54. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80(6):827-41.
  55. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990 [published erratum appears in Int J Cancer 1999 Dec 10;83(6):870-3]. Int J Cancer 1999;83(1):18-29.
  56. Schistosomes, liver flukes and Helicobacter pylori. IARC Working
    Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994;61:1-241.
  57. Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998;114(6):1169-79.
  58. Danesh J. Helicobacter pylori infection and gastric cancer: systematic review of the epidemiological studies. Aliment Pharmacol Ther 1999;13(7):851-6.
  59. Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol 1999;94(9):2373-9.
  60. Brenner H, Arndt V, Sturmer T, Stegmaier C, Ziegler H, Dhom G. Individual and joint contribution of family history and Helicobacter pylori infection to the risk of gastric carcinoma. Cancer 2000;88(2):274-9.
  61. Meining AG, Bayerdorffer E, Stolte M. Helicobacter pylori gastritis of the gastric cancer phenotype in relatives of gastric carcinoma atients. Eur J Gastroenterol Hepatol 1999;11(7):717-20.
  62. Hansen S, Melby KK, Aase S, Jellum E, Vollset SE. Helicobacter pylori infection and risk of cardia cancer and non-cardia gastric cancer. A nested case-control study. Scand J Gastroenterol 1999;34(4):353-60.
  63. Uemura N, Mukai T, Okamoto S, Yamaguchi S, Mashiba H, Taniyama K, et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of
    early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997;6(8):639-42.
  64. Huang JQ, Hunt RH. Helicobacter pylori and gastric cancer - the clinicians' point of view. Aliment Pharmacol Ther 2000;14 Suppl 3:48-54.
  65. Ruskone-Fourmestraux A, Lavergne A, Aegerter PH, Megraud F, Palazzo L, de Mascarel A, et al. Predictive factors for regression of gastric MALT lymphoma after anti- Helicobacter pylori treatment.
    Gut 2001;48(3):297-303.
  66. Morgner A, Bayerdorffer E, Neubauer A, Stolte M. Malignant tumors of the stomach. Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori. Gastroenterol Clin North Am 2000;29(3):593-607.
  67. Ng WW, Lam CP, Chau WK, Fen-Yau Li A, Huang CC, Chang FY, et al. Regression of high-grade gastric mucosa-associated lymphoid tissue lymphoma with Helicobacter pylori after triple antibiotic therapy. Gastrointest Endosc 2000;51(1):93-6.
  68. Raderer M, Pfeffel F, Pohl G, Mannhalter C, Valencak J, Chott A. Regression of colonic low grade B cell lymphoma of the mucosa associated lymphoid tissue type after eradication of Helicobacter pylori. Gut 2000;46(1):133-5.
  69. Oberg S, Peters JH, Nigro JJ, Theisen J, Hagen JA, DeMeester SR, et al. Helicobacter pylori is not associated with the manifestations of gastroesophageal reflux disease. Arch Surg 1999;134(7):722-6.
  70. Manes G, Mosca S, Laccetti M, Lioniello M, Balzano A. Helicobacter pylori infection, pattern of gastritis, and symptoms in erosive and nonerosive gastroesophageal reflux disease [see comments]. Scand J Gastroenterol 1999;34(7):658-62.
  71. El-Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut 1998;43(3):327-33.
  72. Dent J. Helicobacter pylori and reflux disease. Eur J Gastroenterol Hepatol 1999;11 Suppl 2:S51-7; discussion S73.
  73. Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997;112(5):1442-7.
  74. Fallone CA, Barkun AN, Friedman G, Mayrand S, Loo V, Beech R, et al. Is Helicobacter pylori eradication associated with gastroesophageal reflux disease? Am J Gastroenterol 2000;95(4):914-20.
  75. Carbone F, Neri M, Laterza F, al. e. Twenty-four hour esophageal pHmetry in patients with non-ulcer dyspepsia is unchanged after H. pylori eradication (abstract). Gastroenterolgy 1998;114:G0342.
  76. Vakil N, Hahn B, McSorley D. Recurrent symptoms and gastro-oesophageal reflux disease in patients with duodenal ulcer treated for Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14(1):45-
    51.
  77. Olafsson S, Berstad A. Refluks and diarrhea are not long-lasting side-effects of Helicobacter pylori eradication. Abstrakt på Norsk gastroenterologisk forenings årsmøte på Lillehammer 2000
  78. Tefera S, Hatlebakk JG, Berstad A. The effect of Helicobacter pylori eradication on gastro-oesophageal reflux. Aliment Pharmacol Ther 1999;13(7):915-20.
  79. Axon A, Bardhan K, Moayyedi P, Dixon M, Brown L. Does eradication of Helicobacter pylori influence the recurrence of symptoms in patients with symptomatic gastro-esophageal reflux
    disase? A randomised double blind study. Gastroenterology 1999;116:A117.
  80. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Eskes SA, Meuwissen SG. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol 1999;94(4):884-7.
  81. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HP, Liedman B, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996;334(16):1018-22.
  82. Lundell L, Miettinen P, Myrvold HE, Pedersen SA, Thor K, Andersson A, et al. Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. Gastroenterology 1999;117(2):319-26.
  83. Stolte M, Meining A, Schmitz JM, Alexandridis T, Seifert E. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastrooesophageal reflux disease. Aliment Pharmacol Ther 1998;12(3):247-53.
  84. Hawkey CJ. What consideration should be given to Helicobacter pylori in treating nonsteroidal anti-inflammatory drug ulcers? Eur J Gastroenterol Hepatol 2000;12 Suppl 1:S17-20.
  85. Sung J, Russell RI, Nyeomans, Chan FK, Chen S, Fock K, et al. Non-steroidal antiinflammatory drug toxicity in the upper gastrointestinal tract. J Gastroenterol Hepatol 2000;15 Suppl:G58-68.
  86. Huang JQ, Lad RJ, Sridhar S, Sumanac K, Hunt RH. H. pylori infection increases the risk of non-steroidal antiinflammatory drug (NSAID)-induced gastroduodenal ulceration. Gastroenteroly 1999;94:A2271.
  87. Aalykke C, Lauritsen JM, Hallas J, Reinholdt S, Krogfelt K, Lauritsen K. Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: a case-control study. Gastroenterology 1999;116(6): 1305-9.
  88. Hawkey CJ. Risk of ulcer bleeding in patients infected with Helicobacter pylori taking non-steroidal anti-inflammatory drugs. Gut 2000;46(3):310-1.
  89. Santolaria S, Lanas A, Benito R, Perez- Aisa M, Montoro M, Sainz R. Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users. Aliment Pharmacol Ther 1999;13(11):1511-8.
  90. Labenz J, Peitz U, Kohl H, Kaiser J, Malfertheiner P, Hackelsberger A, et al. Helicobacter pylori increases the risk of peptic ulcer bleeding: a case- control study. Ital J Gastroenterol Hepatol 1999;31(2):110-5.
  91. Chan FK, Sung JJ, Chung SC, To KF, Yung MY, Leung VK, et al. Randomised trial of eradication of Helicobacter pylori before non- steroidal anti-inflammatory drug therapy to prevent peptic ulcers.
    Lancet 1997;350(9083) :975-9.
  92. Hawkey CJ, Tulassay Z, Szczepanski L, van Rensburg CJ, Filipowicz-Sosnowska A, Lanas A, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal antiinflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention [published erratum appears in Lancet 1998 Nov 14;352(9140):1634]. Lancet 1998;352(9133):1016-21.
  93. Chan FK, Sung JJ, Suen R, Lee YT, Wu JC, Leung WK, et al. Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective randomized study. Aliment Pharmacol Ther 1998;12(12):1201-5.
  94. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti- inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term
    Arthritis Safety Study. Jama 2000;284(10):1247-55.
  95. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis. N Engl J Med 2000;343(21):1520-1528.
  96. Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999;117(1):17-25.
  97. Dammann HG, Folsch UR, Hahn EG, von Kleist DH, Klor HU, Kirchner T, et al. Eradication of H. pylori with pantoprazole, clarithromycin, and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration. Helicobacter 2000;5(1):41-51.
  98. Wong BC, Xiao SD, Hu FL, Qian SC, Huang NX, Li YY, et al. Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study. Aliment Pharmacol Ther 2000;14(2):217-24.
  99. Moayyedi P, Feltbower R, Crocombe W, Mason S, Atha P, Brown J, et al. The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in a community screen and treat programme. Leeds Help Study Group. Aliment Pharmacol Ther 2000;14(6):719-28.
  100. Berstad A, Olafsson S, Tefera S, Berstad K, Hundal O, Bergseth M, et al. Bismuth therapy for Helicobacter pylori infection. A review of five years experience at a university hospital in Norway. J Physiol Pharmacol 1996;47(1):31-49.
  101. Wilhelmsen I, Weberg R, Berstad K, Hausken T, Hundal O, Berstad A. Helicobacter pylori eradication with bismuth subnitrate, oxytetracycline and metronidazole in patients with peptic ulcer disease. Hepatogastroenterology 1994;41(1):43-7.
  102. Lind T, Veldhuyzen van Zanten S, Unge P, Spiller R, Bayerdorffer E, O'Morain C, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter 1996;1(3):138-44.
  103. Lind T, Megraud F, Unge P, Bayerdorffer E, O'Morain C, Spiller R, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999;116(2):248-53.
  104. Zanten SJ, Bradette M, Farley A, Leddin D, Lind T, Unge P, et al. The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment Pharmacol Ther 1999;13(3):289-95.
  105. Malfertheiner P, Bayerdorffer E, Diete U, Gil J, Lind T, Misiuna P, et al. The GUMACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther 1999;13(6):703-12.
  106. Veldhuyzen Van Zanten S, Lauritsen K, Delchier JC, Labenz J, De Argila CM, Lind T, et al. One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease. Aliment Pharmacol Ther 2000;14(12):1605-1611.
  107. van der Hulst RW, Keller JJ, Rauws EA, Tytgat GN. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter 1996;1(1):6-19.
  108. Veldhuyzen van Zanten S, Hunt RH, Cockeram A, Schep G, Malatjalian D, Sidorov J, et al. Adding once-daily omeprazole 20 mg to metronidazole/amoxicillin treatment for Helicobacter pylori gastritis: a randomized, double-blind trial showing the importance of metronidazole resistance. Am J Gastroenterol 1998;93(1):5-10.
  109. Huang J, Hunt RH. The importance of clarithromycin dose in the management of Helicobacter pylori infection: a metaanalysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. Aliment Pharmacol Ther 1999;13(6):719-29.
  110. Cammarota G, Tursi A, Papa A, Montalto M, Veneto G, Cuoco L, et al. Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin. Aliment Pharmacol Ther 1996;10(6):997-1000.
  111. Pohle T, Stoll R, Kirchner T, Heep M, Lehn N, Bock H, et al. Eradication of Helicobacter pylori with lansoprazole, roxithromycin and metronidazole--an open pilot study. Aliment Pharmacol Ther 1998;12(12):1273-8.
  112. Olafsson S, Berstad A, Bang CJ, Nysaeter G, Coll P, Tefera S, et al. Spiramycin is comparable to oxytetracycline in eradicating H. pyloriwhen given with ranitidine bismuth citrate and metronidazole. Aliment Pharmacol Ther 1999;13(5):651-9.
  113. Chiba N, Marshall CP. Omeprazole once or twice daily with clarithromycin and metronidazole for Helicobacter pylori. Can J Gastroenterol 2000;14(1):27-31.
  114. Bardhan KD, Wurzer H, Marcelino M, Jahnsen J, Lotay N, Roberts PM. Ranitidine bismuth citrate with clarithromycin given twice daily
    effectively eradicates Helicobacter pylori and heals duodenal ulcers [published erratum appears in Am J Gastroenterol 1999 Jan;94(1):298]. Am J Gastroenterol 1998;93(3):380-5.
  115. Catalano F, Catanzaro R, Bentivegna C, Brogna A, Condorelli G, Cipolla R. Ranitidine bismuth citrate versus omeprazole triple therapy for the eradication of Helicobacter pylori and healing of duodenal ulcer. Aliment Pharmacol Ther 1998;12(1):59-62.
  116. van der Wouden EJ, Thijs JC, van Zwet AA, Kooy A, Kleibeuker JH. One-week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two-week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection: a randomized, clinical trial. Am J Gastroenterol 1998;93(8):1228-31.
  117. Vakil N, Cutler A. Ten-day triple therapy with ranitidine bismuth citrate, amoxicillin, and clarithromycin in eradicating Helicobacter pylori. Am J Gastroenterol 1999;94(5):1197-9.
  118. Mao HV, Lak BV, Long T, Chung NQ, Thang DM, Hop TV, et al. Omeprazole or ranitidine bismuth citrate triple therapy to treat Helicobacter pylori infection: a randomized, controlled trial in Vietnamese patients with duodenal ulcer. Aliment Pharmacol Ther
    2000;14(1):97-101.
  119. Spinzi GC, Boni F, Bortoli A, Colombo E, Ballardini G, Venturelli R, et al. Seven-day triple therapy with ranitidine bismuth citrate or omeprazole and two antibiotics for eradication of Helicobacter pylori in duodenal ulcer: a multicentre, randomized, single-blind study. Aliment Pharmacol Ther 2000;14(3):325-30.
  120. Sung JJ, Chan FK, Wu JC, Leung WK, Suen R, Ling TK, et al. One-week ranitidine bismuth citrate in combinations with metronidazole,
    amoxycillin and clarithromycin in the treatment of Helicobacter pylori
    infection: the RBC-MACH study. Aliment Pharmacol Ther 1999;13(8):1079-84.
  121. Smoot DT, Hinds T, Ashktorab H, Jagtap J, Kim KS, Scott VF. Effectiveness of ranitidine bismuth citrate, clarithromycin, and metronidazole therapy for treating Helicobacter pylori. Am J Gastroenterol 1999;94(4):955-8.
  122. Laheij RJ, Rossum LG, Jansen JB, Straatman H, Verbeek AL. Evaluation of treatment regimens to cure Helicobacter pylori infection-- a meta-analysis. Aliment Pharmacol Ther 1999;13(7):857-64.
  123. Tulassay Z, Kryszewski A, Dite P, Kleczkowiski D, Rudzinski J, Bartuz Z, et al. 7-day treatment with esomeprazole-based triple therapy eradicates H. pylori (Hp) and heals patients with duodenal ulcer (DU) disease. Gastroenterology 2000;118:A502.
  124. Dore MP, Leandro G, Realdi G, Sepulveda AR, Graham DY. Effect of
    pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta- analytical approach. Dig Dis Sci 2000;45(1):68-76.
  125. Houben MH, Van Der Beek D, Hensen EF, Craen AJ, Rauws EA, Tytgat GN. A systematic review of Helicobacter pylori eradication therapy--the impact of antimicrobial resistance on eradication
    rates. Aliment Pharmacol Ther 1999;13(8):1047-55.
  126. Megraud F. Resistance of Helicobacter pylori to antibiotics: the main limitation of current proton-pump inhibitor triple therapy. Eur J Gastroenterol Hepatol 1999;11 Suppl 2:S35-7; discussion S43-5.
  127. de Boer WA. Bismuth triple therapy: still a very important drug regimen for curing Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1999;11(7):697-700.
  128. Houben MH, Hensen EF, Rauws EA, Hulst RW, Hoff BW, Ende AV, et al. Randomized trial of omeprazole and clarithromycin combined with either metronidazole or amoxycillin in patients with metronidazole-resistant or -susceptible Helicobacter pylori
    strains. Aliment Pharmacol Ther 1999;13(7):883-9.
  129. Megraud F, Lehn N, Lind T, Bayerdorffer E, O'Morain C, Spiller R, et al. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother 1999;43(11):2747- 52.
  130. Kearney DJ, Brousal A. Treatment of Helicobacter pylori infection in clinical practice in the United States: results from 224 patients. Dig Dis Sci 2000;45(2):265-71.
  131. van Doorn LJ, Schneeberger PM, Nouhan N, Plaisier AP, Quint WG, de Boer WA. Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment. Gut 2000;46(3):321-6.
  132. Lee JM, Breslin NP, Hyde DK, Buckley MJ, O'Morain CA. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther 1999;13(4):489-96.
  133. Chan FK, Sung JJ, Suen R, Wu JC, Ling TK, Chung SC. Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies. Aliment Pharmacol Ther 2000;14(1):91-5.
  134. Huang JQ, Hunt RH. Treatment after failure: the problem of «non-responders». Gut 1999;45 Suppl 1:I40-4.
  135. Gasbarrini A, Ojetti V, Armuzzi A, Branca G, Canducci F, Torre ES, et al. Efficacy of a multistep strategy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000;14(1):79-83.
  136. Sherman P, Hassall E, Hunt RH, Fallone CA, Veldhuyzen Van Zanten S, Thomson AB. Canadian Helicobacter Study Group Consensus Conference on the Approach to Helicobacter pylori Infection in Children and Adolescents. Can J Gastroenterol 1999;13(7):553-9.
  137. Drumm B, Koletzko S, Oderda G. Helicobacter pylori infection in
    children: a consensus statement. European Paediatric Task Force on
    Helicobacter pylori. J Pediatr Gastroenterol Nutr 2000;30(2):207-13.
  138. Dohil R, Hassall E. Peptic ulcer disease in children. Baillieres Best Pract Res Clin Gastroenterol 2000;14(1):53-73.
  139. Perminow G, Rydning A, Jacobsen CD, Frigessi A. Gastrointestinal endoscopy of children. Tidsskr Nor Lægeforen 2000;120:3503-6.
  140. Hassall E, Hiruki T, Dimmick JE. True Helicobacter pylori-negative duodenal ulcer disease in children. Gastroenterology 1993;104:A96.
  141. Perri F, Pastore M, Clemente R, Festa V, Quitadamo M, Niro G, et al. Helicobacter pylori infection may undergo spontaneous eradication in children: a 2-year follow-up study. J Pediatr Gastroenterol Nutr
    1998;27(2):181-3.
  142. Tindberg Y, Blennow M, Granstrom M. Clinical symptoms and social factors in a cohort of children spontaneously clearing Helicobacter pylori infection. Acta Paediatr 1999;88(6):631-5.
  143. Rowland M, Kumar D, Daly L, O'Connor P, Vaughan D, Drumm B.
    Low rates of Helicobacter pylori reinfection in children. Gastroenterology 1999;117(2):336-41.
  144. Rowland M, Imrie C, Bourke B, Drumm B. How should Helicobacter pylori infected children be managed? Gut 1999;45 Suppl 1:I36-9.
  145. Elitsur Y, Neace C. Detection of Helicobacter pylori organisms by Hpfast in children. Dig Dis Sci 1999;44(6):1169-72.
  146. Corvaglia L, Bontems P, Devaster JM, Heimann P, Glupczynski Y, Keppens E, et al. Accuracy of serology and 13C-urea breath test for detection of Helicobacter pylori in children. Pediatr Infect Dis J 1999;18(11):976-9.
  147. Kindermann A, Demmelmair H, Koletzko B, Krauss-Etschmann S,
    Wiebecke B, Koletzko S. Influence of age on 13C-urea breath test results in children [published erratum appears in J Pediatr Gastroenterol Nutr 2000 Mar;30(3):354]. J Pediatr Gastroenterol Nutr 2000;30(1):85-91.
  148. Oderda G, Rapa A, Ronchi B, Lerro P, Pastore M, Staiano A, et al. Detection of Helicobacter pylori in stool specimens by non-invasive antigen enzyme immunoassay in children: multicentre Italian study. Bmj 2000;320(7231):347-8.
  149. Frank F, Stricker T, Stallmach T, Braegger CP. Helicobacter pylori
    infection in recurrent abdominal pain. J Pediatr Gastroenterol Nutr 2000;31- (4):424-7.
  150. Fluge G. Gastrointestinale endoskopier av barn (Lederartikkel). Tidsskr Nor Lægeforen 2000;120:3502.
  151. Dohil R, Israel DM, Hassall E. Effective 2- wk therapy for Helicobacter pylori disease in children. Am J Gastroenterol 1997;92(2):244-7.
  152. Tiren U, Sandstedt B, Finkel Y. Helicobacter pylori gastritis in children: efficacy of 2 weeks of treatment with clarithromycin, amoxicillin and omeprazole. Acta Paediatr 1999;88(2):166-8.
  153. Shashidhar H, Peters J, Lin CH, Rabah R, Thomas R, Tolia V. A prospective trial of lansoprazole triple therapy for pediatric Helicobacter pylori infection. J Pediatr Gastroenterol Nutr 2000;30(3):276-82.
  154. Behrens R, Lang T, Keller KM, Bindl L, Becker M, Rodeck B, et al. Dual versus triple therapy of Helicobacter pylori infection: results of a multicentre trial. Arch Dis Child 1999;81(1):68-70.
  155. Kato S, Ritsuno H, Ohnuma K, Iinuma K, Sugiyama T, Asaka M. Safety and efficacy of one-week triple therapy for eradicating Helicobacter pylori in children. Helicobacter 1998;3(4):278-82.
  156. Casswall TH, Alfven G, Drapinski M, Bergstrom M, Dahlstrom KA.
    One-week treatment with omeprazole, clarithromycin, and metronidazole in children with Helicobacter pylori infection. J
    Pediatr Gastroenterol Nutr 1998;27(4):415-8.
  157. Moshkowitz M, Reif S, Brill S, Ringel Y, Arber N, Halpern Z, et al. One- Week Triple Therapy With Omeprazole, Clarithromycin, and
    Nitroimidazole for Helicobacter pylori Infection in Children and Adolescents. Pediatr Electron Pages 1998;102(1):e14.
  158. Pilotto A, Franceschi M, Leandro G, Bozzola L, Fortunato A, Rassu M, et al. Efficacy of 7 day lansoprazolebased triple therapy for Helicobacter pylori infection in elderly patients. J Gastroenterol Hepatol 1999;14(5):468-75.
  159. Pilotto A, Franceschi M, Di Mario F, Leandro G, Bozzola L, Valerio G. The long-term clinical outcome of elderly patients with Helicobacter pyloriassociated peptic ulcer disease. Gerontology 1998;44(3):153-8.
  160. Moshkowitz M, Brill S, Konikoff FM, Reif S, Arber N, Halpern Z. The
    efficacy of omeprazole-based shortterm triple therapy in Helicobacter
    pylori-positive older patients with dyspepsia. J Am Geriatr Soc 1999;47(6):720-2.
  161. Olbe L, Fandriks L, Hamlet A, Svennerholm AM. Conceivable
    mechanisms by which Helicobacter pylori provokes duodenal ulcer
    disease. Baillieres Best Pract Res Clin Gastroenterol 2000;14(1):1-12.
  162. Hamlet A, Thoreson AC, Nilsson O, Svennerholm AM, Olbe L. Duodenal Helicobacter pylori infection differs in cagA genotype between asymptomatic subjects and patients with duodenal ulcers.
    Gastroenterology 1999;116(2):259- 68.
  163. McColl KE, Gillen D, El-Omar E. The role of gastrin in ulcer
    pathogenesis. Baillieres Best Pract Res Clin Gastroenterol
    2000;14(1):13-26.
  164. Peura DA, Graham DY. Helicobacter pylori: consensus reached: peptic ulcer is on the way to becoming an historic disease [editorial]. Am J Gastroenterol 1994;89(8):1137-9.
  165. Peura DA. The problem of Helicobacter pylori-negative idiopathic ulcer disease. Baillieres Best Pract Res Clin Gastroenterol 2000;14(1):109-17.
  166. Cutler AF. Testing for Helicobacter pylori in clinical practice. Am J Med 1996;100(5A):35S-39S; discussion 39S-41S.
  167. Parsonnet J. The incidence of Helicobacter pylori infection. Aliment Pharmacol Ther 1995;9(Suppl 2):45-51.
  168. Ciociola AA, McSorley DJ, Turner K, Sykes D, Palmer JB. Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Am J Gastroenterol 1999;94(7):1834-40.
  169. Laine L, Hopkins RJ, Girardi LS. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A
    meta-analysis of rigorously designed trials. Am J Gastroenterol 1998;93(9):1409-15.
  170. Kemppainen H, Raiha I, Sourander L. Clinical presentation of peptic ulcer in the elderly. Gerontology 1997;43(5):283-8.
  171. Henry A, Batey RG. Low prevalence of Helicobacter pylori in an Australian duodenal ulcer population: NSAIDitis or the effect of ten years of H. pylori treatment? [letter]. Aust N Z J Med 1998;28(3):345.
  172. Xia H, Phung N, Kalender J, Talley NJ. Characteristics of Helicobacter pylori positive and negative peptic ulcer disease. Gastroenterology
    1999;116:A359.
  173. Gisbert JP, Blanco M, Mateos JM, Fernandez-Salazar L, Fernandez-
    Bermejo M, Cantero J, et al. H. pylorinegative duodenal ulcer prevalence and causes in 774 patients. Dig Dis Sci 1999;44(11):2295-302.
  174. Lanas A. NSAID use and abuse in gastroenterology: refractory peptic
    ulcers. Acta Gastroenterol Belg 1999;62(4):418-20.
  175. McColl KE, el-Nujumi AM, Chittajallu RS, Dahill SW, Dorrian CA, el-Omar E, et al. A study of the pathogenesis of Helicobacter pylori negative chronic duodenal ulceration. Gut 1993;34(6):- 762-8.
  176. Harris AW, Gummett PA, Phull PS, Jacyna MR, Misiewicz JJ, Baron JH. Recurrence of duodenal ulcer after Helicobacter pylori eradication is related to high acid output. Aliment Pharmacol Ther 1997;11-(2):331-4.
  177. Reinbach DH, Cruickshank G, McColl KE. Acute perforated duodenal ulcer is not associated with Helicobacter pylori infection. Gut 1993;34(10):1344-7.
  178. Gillen D, Wirz AA, Neithercut WD, Ardill JE, McColl KE. Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by
    omeprazole. Gut 1999;44(4):468-75.
  179. Silverstein MD, Petterson T, Talley NJ. Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia: a decision analysis. Gastroenterology 1996;110(1):72-83.
  180. American Gastroenterological Association medical position
    statement: evaluation of dyspepsia. Gastroenterology 1998;114(3):579- 81.
  181. Lassen AT, Pedersen FM, Bytzer P, Schaffalitzky de Muckadell OB.
    Helicobacter pylori test-and-eradicate versus prompt endoscopy for
    management of dyspeptic patients: a randomised trial. Lancet
    2000;356(9228):455-60.
  182. Heaney A, Collins JS, Watson RG, McFarland RJ, Bamford KB, Tham TC. A prospective randomised trial of a «test and treat» policy versus endoscopy based management in young Helicobacter pylori positive patients with ulcer-like dyspepsia, referred to a hospital clinic. Gut 1999;45(2):186- 90.
  183. Ladabaum U, Fendrick AM, Schieman JM. Utilization and outcomes of office based testing for Helicobacter pylori (HP) in symptomatic primary care patients. Gastroenterology 1998;114:A24.
  184. Moayyedi P, Feltbower R, Brown J, Mason S, Mason J, Nathan J, et al. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Leeds HELP Study Group. Lancet 2000;355(9216):1665-9.
  • Avansert søk

Quick Links

  • Bestill materiale
  • Forsiden for alle
  • Kontakt oss

Verktøy

  • Utskriftsvennlig versjon
  • Lag bokmerke for nettstedet

Related Links

  • Preparatomtale

For helsepersonell

secondary logo alt text to be displayed

Legal notices

  • Vilkår for bruk
  • Personvern
  • © AstraZeneca 2010